Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors

Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors

Immune checkpoint inhibitors (ICIs) have led recent advances in the field of cancer immunotherapy improving overall survival in multiple malignancies with abysmal prognoses prior to their introduction. The remarkable efficacy of ICIs is however limited by their potential for systemic and organ speci...

Full description

Bibliographic Details
Main Authors: Omoruyi Credit Irabor, Nicolas Nelson, Yash Shah, Muneeb Khan Niazi, Spencer Poiset, Eugene Storozynsky, Dinender K. Singla, Douglas Craig Hooper, Bo Lu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Oncology
Subjects:
immune checkpoint inhibitor (ICI)
Cardiotoxic adverse effect
immunotherapy
anti PD-1 antibodies
anti CTLA-4 antibodies
anti PD-L1 therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.940127/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.940127/full

Similar Items